|
1）Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U. S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007; 356: 2388-98
|
|
|
|
2）Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006; 17: 2034-47
|
|
|
|
|
|
3）US renal data system. Excerpts from the USRDS. 2006. Annual data report. Am J Kidney Dis. 2006; 49: S1-296
|
|
|
|
|
|
4）Muntner P, Mann D, Winston J, et al. Serum cystatin C and increased coronary heart disease prevalence in US adults without chronic kidney disease. Am J Cardiol. 2008; 102: 54-7
|
|
|
|
|
|
5）Parikh NI, Hwang SJ, Larson MG, et al. Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch Intern Med. 2006; 166: 1884-91
|
|
|
|
|
|
6）Muntner P, He J, Astor BC, et al. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol. 2005; 16: 529-38
|
|
|
|
|
|
7）Chonchol M, Whittle J, Desbien A, et al. Chronic kidney disease is associated with angiographic coronary artery disease. Am J Nephrol. 2008; 28: 354-60
|
|
|
|
|
|
8）Weiner DE, Tighiouart H, Elsayed EF, et al. The relationship between nontraditional risk factors and outcomes in individuals with stage 3 to 4 CKD. Am J Kidney Dis. 2008; 51: 212-23
|
|
|
|
|
|
9）Kovesdy CP, Anderson JE. Reverse epidemiology in patients with chronic kidney disease who are not yet on dialysis. Semin Dial. 2007; 20: 566-9
|
|
|
|
|
|
10）Shah DS, Polkinhorne KR, Pellicano R, et al. Are traditional risk factors valid for assessing cardiovascular risk in end-stage renal failure patients? Nephrology (Carlton). 2008; 13: 667-71
|
|
|
|
|
|
11）Kalantar-Zadeh K, Block G, Horwich T, et al. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol. 2004; 43: 1439-44
|
|
|
|
|
|
12）Parekh RS, Plantinga LC, Kao WH, et al. The association of sudden cardiac death with inflammation and other traditional risk factors. Kidney Int. 2008; 74: 1335-42
|
|
|
|
|
|
13）de Mutsert R, Grootendorst DC, Axelsson J, et al. Excess mortality due to interaction between protein-energy wasting, inflammation and cardiovascular disease in chronic dialysis patients. Nephrol Dial Transplant. 2008; 23: 2957-64
|
|
|
|
|
|
14）Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 2008; 73: 391-8
|
|
|
|
|
|
15）Kendrick J, Chonchol MB. Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat Clin Pract Nephrol. 2008; 4: 672-81
|
|
|
|
|
|
16）Honda H, Qureshi AR, Heimburger O, et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis. 2006; 47: 139-48
|
|
|
|
|
|
17）Soriano S, Gonzalez L, Martin-Malo A, et al. C-reactive protein and low albumin are predictors of morbidity and cardiovascular events in chronic kidney disease (CKD) 3-5 patients. Clin Nephrol. 2007; 67: 352-7
|
|
|
|
|
|
18）Senti M, Romero R, Pedro-Botet J, et al. Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. Kidney Int. 1992; 41: 1394-9
|
|
|
|
|
|
19）Yamamoto S, Kon V. Mechanisms for increased cardiovascular disease in chronic kidney dysfunction. Curr Opin Nephrol Hypertens. 2009; 18: 181-8
|
|
|
|
|
|
20）Maggi E, Bellazzi R, Falaschi F, et al. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis? Kidney Int. 1994; 45: 876-83
|
|
|
|
|
|
21）Honda H, Ueda M, Kojima S, et al. Oxidized high-density lipoprotein as a risk factor for cardiovascular events in prevalent hemodialysis patients. Atherosclerosis. 2012; 220: 493-501
|
|
|
|
|
|
22）Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011; 377: 2181-92
|
|
|
|
|
|
23）Kilpatrick RD, McAllister CJ, Kovesdy CP, et al. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol. 2007; 18: 293-303
|
|
|
|
|
|
24）Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009; 360: 1395-407
|
|
|
|
|
|
25）Yamamoto S, Yancey PG, Zuo Y, et al. Macrophage polarization by angiotensin II-type 1 receptor aggravates renal injury-acceleration of atherosclerosis. Arterioscler Thromb Vasc Biol. 2011; 31: 2856-64
|
|
|
|
|
|
26）Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 364: 127-35
|
|
|
|
|
|
27）Yamamoto S, Yancey PG, Ikizler TA, et al. Dysfunctional high-density lipoprotein in patients with chronic hemodialysis. J Am Coll Cardiol. in press
|
|
|
|
|
|
28）Holzer M, Birner-Gruenberger R, Stojakovic T, et al. Uremia alters HDL composition and function. J Am Soc Nephrol. 2011; 22: 1631-41
|
|
|
|
|